Anatomic Stage IV Breast Cancer AJCC v8Phase 2NCT04305834
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
A Phase 2 study testing Abemaciclib and Questionnaire Administration in people with Anatomic Stage IV Breast Cancer AJCC v8 and Hormone Receptor Positive Breast Carcinoma, run by City of Hope Medical Center at 6 sites in United States.
Trial summary
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body. Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma
- What is being tested?
- Abemaciclib and Questionnaire Administration
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 43 participants
- Where
- 6 sitesUnited States
- Study dates
- 5 Jun 2020to 21 May 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Documented informed consent of the participant
- Age >= 70 years
- Life expectancy > 6 months
- Ability to read and understand English or Spanish
- Measurable or non-measurable disease
- Histologically or cytologically confirmed diagnosis of:
Show all 26Show fewer
- Estrogen-receptor positive and/or progesterone receptor positive breast cancer determined by immunohistochemistry (IHC) methods according to the local institution standard protocol
- HER2-negative breast cancer defined as negative if the IHC status is 0 or 1+, or if IHC is 2+ and in situ hybridization assay is negative per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
- Radiographically confirmed metastatic breast cancer
- Progressed on prior endocrine therapy or palbociclib or ribociclib or chemotherapy
- Patients who received chemotherapy recovered from the acute side effects to prior cancer therapy (except alopecia or residual grade 2 peripheral neuropathy) to =< grade 1 or baseline. A washout period of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy)
- Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization
- Absence of central nervous system (CNS) involvement unless they meet ONE of the following criteria:
- Untreated brain metastases (e.g., lesions < 1 cm) not needing immediate local therapy
- Previously treated brain metastases not needing immediate local therapy
- At least 4 weeks from the last date of prior therapy completion (including radiation and/or surgery) to starting the study treatment
- Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
- Absence of interstitial lung disease/pneumonitis
- Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
- Platelets >= 100 x 10^9/L
- Hemoglobin >= 8 g/dL
- (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion)
- In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN)
- If the patient has liver metastases, ALT and AST < 5 x ULN
- In patients without Gilbert's syndrome, total bilirubin =< 1.5 x ULN; In patients with Gilbert's syndrome, total bilirubin =< 2.0 x ULN or direct bilirubin within normal limits (WLN)
- Creatinine clearance of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Who cannot join
- Major surgery within 14 days prior to receiving study drug or has not recovered from major side effect
- Patient is currently receiving any of the prohibited medications detailed below and cannot be discontinued 7 days prior to starting study drug
- Other investigational therapy should be given to participants
- Anticancer agents other than the study medications administered as part of this study protocol should be given to participants. If such agents are required for a participant then the participant must first be withdrawn from the study
- Co-medication that may interfere with study results; e.g. immune-suppressive agents other than corticosteroids, such as systemic cyclosporine and tacrolimus are prohibited during the treatment phase of the study, unless discussed with principal investigator felt to be of low clinical risk to the participant
- Use of herbal medications may have unknown interactions with the metabolism of the study agents, and therefore are prohibited from use during the treatment phase of the trial
Show all 15Show fewer
- Known hypersensitivity to any of the excipients of abemaciclib
- Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C (for example, hepatitis B surface antigen positive). Screening is not required for enrollment
- Impairment of gastrointestinal (GI) function or GI disease that in the investigator's opinion may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
- History of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
- Patient has any other concurrent severe or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis)
- Inability to swallow oral medications
- Serious or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance < 30 ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea)
- History of non-compliance to medical regimen
- Patients with a prior malignancy diagnosed within 2 years and with evidence of disease (except adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
6 sites in 1 country
United States6 sites, 6 recruiting
- Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
Rachel Freedman, MD, 617-632-3000, Rachel_Freedman@dfci.harvard.edu
- Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203
Ellis Levine, MD, 1-800-767-9355, Ellis.Levine@RosewellPark.org
- Recruiting
City of Hope Medical Center
Duarte, California, 91010
Mina Sedrak, 626-256-4673 ext. 89200, msedrak@coh.org
Mina Sedrak
- Recruiting
City of Hope at Irvine Lennar
Irvine, California, 92618
Thanh Nga Doan, 6262184673, tdoan@coh.org
- Recruiting
City of Hope at Long Beach Elm
Long Beach, California, 90813
Thanh Nga Doan, 6262184673, tdoan@coh.org
- Recruiting
City of Hope South Pasadena
South Pasadena, California, 91030
Thanh Nga Doan, 6262184673, mrosenzweig@coh.org
About this study
Official title: A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Read the detailed description
PRIMARY OBJECTIVE:
- To estimate the incidence of grade 3 or higher toxicities attributed to abemaciclib monotherapy in adults aged 70 or older with hormone receptor positive metastatic breast cancer.
SECONDARY OBJECTIVES:
- To describe the full toxicity profile including all grade 2 and higher adverse events, and patient-reported adverse events (AEs) using Patients Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) measures.
II. To describe rates of dose reductions, dose holds, treatment discontinuations due to factors other than progression, and hospitalizations.
III. To estimate median (and 95% confidence interval [CI]) failure-free survival, progression-free survival and overall survival.
IV. To describe the results of Was It Worth It (WIWI) and Overall Treatment Utility (OTU) questionnaires.
- To describe the rate of adherence to abemaciclib. VI. To determine average plasma steady-state abemaciclib Ctrough concentrations.
VII. To evaluate the association of adherence rate with abemaciclib plasma t-rough concentrations.
VIII. To describe associations between cancer-specific, comprehensive Geriatric Assessment (cGA) scores and the incidence of toxicities and their grade.
EXPLORATORY OBJECTIVE:
- To determine the association between biomarkers of aging and grades 3 or higher toxicity.
OUTLINE:
Patients receive abemaciclib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then every 6 months for 2 years.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Being tested
- Abemaciclib, Questionnaire Administration
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AbemaciclibDrug
Also called LY-2835219, LY2835219, Verzenio
Given PO
Questionnaire AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Treatment (abemaciclib) | Experimental | Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Receives: Drug: Abemaciclib; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of grade 3 or higher toxicities
Adverse events will be characterized using the descriptions and grading scales found in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v). 5.0.
Measured: Up to 30 days post treatment
Secondary outcomes (16)
Incidence of toxicities
Toxicities will be graded and named according to CTCAE v. 5.0.
Measured: Up to 30 days post treatment
Incidence of toxicities
Toxicities will be captured by Patient Reported Outcome (PRO)-CTCAE.
Measured: Up to cycle 6
Dose reductions
Will assess rates of dose reductions.
Measured: Up to cycle 6
Dose holds
Will assess rates of dose holds.
Measured: Up to 30 days post treatment
Treatment discontinuations due to factors other than progression
Will assess rates of treatment discontinuations.
Measured: Up to 30 days post treatment
Hospitalizations
Will assess rates of hospitalizations.
Measured: Up to 2 years post treatment
Time to end of treatment
Will estimate median (and 95% confidence interval [CI]) failure-free survival using Kaplan-Meier estimates and through Cox regression to adjust for covariates.
Measured: Up to end of treatment
Progression free survival
Will estimate median (and 95% CI) progression-free survival using Kaplan-Meier estimates and through Cox regression to adjust for covariates.
Measured: Up to 2 years post treatment
Overall survival
Will estimate median (and 95% CI) overall survival using Kaplan-Meier estimates and through Cox regression to adjust for covariates.
Measured: Up to 2 years post treatment
Was It Worth It (WIWI) response
Will be assessed using the WIWI questionnaire.
Measured: Up to end of treatment
Overall treatment utility (OTU) response
Will be assessed using the OTU questionnaire.
Measured: Up to end of treatment
Adherence to abemaciclib
Adherence defined as taking 90% of scheduled doses per cycle. Scheduled doses are assigned doses for the participant which may vary per participant depending on whether or not there a hold in treatment. Adherence will be calculated based on consolidation of pill diary with returned unused pills, and, for City of Hope (COH) Duarte patients, Medication Event Monitoring bottle caps.
Measured: Up to end of treatment
Average plasma steady-state abemaciclib C-trough concentrations
Measured: Up to 2 years post treatment
Pharmacokinetic (PK) parameter of plasma trough concentration
Will evaluate the association of adherence rate with abemaciclib plasma trough concentrations.
Measured: Up to 2 years post treatment
Geriatric assessment scores
Domains include: functional status, co-morbid medical conditions, cognitive function, nutritional status, social support and psychological state, and a review of medications.
Measured: Up to 2 years post treatment
Incidence of toxicities attributable to agent
Graded by CTCAE v 5.0.
Measured: Up to 2 years post treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2020
- Study start5 Jun 2020
- Primary completion21 May 2027 (estimated)
- Study completion21 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anatomic Stage IV Breast Cancer AJCC v8Studies of the same condition, open and under way.
- More trials run by City of Hope Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 43 participants (estimated)
Sponsor and investigators
- Lead sponsor
- City of Hope Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Joanne Mortimer, MD, Principal investigator, City of Hope Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04305834
- Sponsor's protocol ID
- 19206
- Other IDs
- NCI-2019-08847, 19206, P30CA033572
- Status last verified
- Oct 2026
- First submitted
- 2 Mar 2020
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition
- ClinicalTrials.gov ID
- NCT04305834
- Acronym / sponsor ID
- 19206
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 43 participants (estimated)
- Lead sponsor
- City of Hope Medical CenterUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 5 Jun 2020 (actual)
- Primary completion
- 21 May 2027 (estimated)
- Study completion
- 21 May 2027 (estimated)
- First posted
- 12 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Detailed description
PRIMARY OBJECTIVE:
- To estimate the incidence of grade 3 or higher toxicities attributed to abemaciclib monotherapy in adults aged 70 or older with hormone receptor positive metastatic breast cancer.
SECONDARY OBJECTIVES:
- To describe the full toxicity profile including all grade 2 and higher adverse events, and patient-reported adverse events (AEs) using Patients Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) measures.
II. To describe rates of dose reductions, dose holds, treatment discontinuations due to factors other than progression, and hospitalizations.
III. To estimate median (and 95% confidence interval [CI]) failure-free survival, progression-free survival and overall survival.
IV. To describe the results of Was It Worth It (WIWI) and Overall Treatment Utility (OTU) questionnaires.
- To describe the rate of adherence to abemaciclib. VI. To determine average plasma steady-state abemaciclib Ctrough concentrations.
VII. To evaluate the association of adherence rate with abemaciclib plasma t-rough concentrations.
VIII. To describe associations between cancer-specific, comprehensive Geriatric Assessment (cGA) scores and the incidence of toxicities and their grade.
EXPLORATORY OBJECTIVE:
- To determine the association between biomarkers of aging and grades 3 or higher toxicity.
OUTLINE:
Patients receive abemaciclib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then every 6 months for 2 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment (abemaciclib) | Experimental | Drug: Abemaciclib, Other: Questionnaire AdministrationPatients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (26 listed)
- Documented informed consent of the participant
- Age >= 70 years
- Life expectancy > 6 months
- Ability to read and understand English or Spanish
- Measurable or non-measurable disease
Key exclusion criteria (15 listed)
- Major surgery within 14 days prior to receiving study drug or has not recovered from major side effect
- Patient is currently receiving any of the prohibited medications detailed below and cannot be discontinued 7 days prior to starting study drug
- Known hypersensitivity to any of the excipients of abemaciclib
- Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C (for example, hepatitis B surface antigen positive). Screening is not required for enrollment
- Impairment of gastrointestinal (GI) function or GI disease that in the investigator's opinion may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AbemaciclibAlso: LY-2835219, LY2835219, VerzenioGiven PO | Drug | Treatment (abemaciclib) |
| Questionnaire AdministrationAncillary studies | Other | Treatment (abemaciclib) |
Primary outcome
Incidence of grade 3 or higher toxicities
Time frame: Up to 30 days post treatment
Adverse events will be characterized using the descriptions and grading scales found in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v). 5.0.
16 secondary outcomes
Incidence of toxicities
Time frame: Up to 30 days post treatment
Incidence of toxicities
Time frame: Up to cycle 6
Dose reductions
Time frame: Up to cycle 6
Dose holds
Time frame: Up to 30 days post treatment
Treatment discontinuations due to factors other than progression
Time frame: Up to 30 days post treatment
Hospitalizations
Time frame: Up to 2 years post treatment
Time to end of treatment
Time frame: Up to end of treatment
Progression free survival
Time frame: Up to 2 years post treatment
Overall survival
Time frame: Up to 2 years post treatment
Was It Worth It (WIWI) response
Time frame: Up to end of treatment
Overall treatment utility (OTU) response
Time frame: Up to end of treatment
Adherence to abemaciclib
Time frame: Up to end of treatment
Average plasma steady-state abemaciclib C-trough concentrations
Time frame: Up to 2 years post treatment
Pharmacokinetic (PK) parameter of plasma trough concentration
Time frame: Up to 2 years post treatment
Geriatric assessment scores
Time frame: Up to 2 years post treatment
Incidence of toxicities attributable to agent
Time frame: Up to 2 years post treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
Related trials for Anatomic Stage IV Breast Cancer AJCC v8
RecruitingPhase 2
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Active, not recruitingPhase 2
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Active, not recruiting
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
Breast Cancer, Stage IV Breast Cancer
Active, not recruitingPhase 2
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joanne Mortimer, MD principal investigator
City of Hope Medical Center
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Abemaciclib and Questionnaire Administration in people with Anatomic Stage IV Breast Cancer AJCC v8 and Hormone Receptor Positive Breast Carcinoma, run by City of Hope Medical Center at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 26 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joanne Mortimer, MD (626-359-8111, jmortimer@coh.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of grade 3 or higher toxicities (time frame: Up to 30 days post treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.